On October 14, 2022 PharmaMar (MSE:PHM) reported that it has been rated "Excellent" by the Spanish Technical Committee for the Program to Promote Competitiveness in the Pharmaceutical Industry (PROFARMA) (Press release, PharmaMar, OCT 14, 2022, https://pharmamar.com/en/the-profarma-program-grants-pharmamar-an-excellent-company-rating/ [SID1234622023]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company obtained this rating for the seventeenth consecutive time, following an evaluation of the results obtained by analyzing PharmaMar on the basis of industrial, economic and R&D parameters, within the current framework of the Spanish industry. The main objective of the PROFARMA Plan is to increase the competitiveness of the pharmaceutical industry in Spain by modernizing the sector and promoting activities that provide greater added value.

PharmaMar is part of Group A, which is comprised of companies with a significant research activity and resources that position them as leaders in R&D. PharmaMar has both a pharmaceutical production plant and its own research and development center, ranging from non-clinical to clinical stages, and is developing numerous collaborations with leading academic centers and hospitals around the world.